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Abstract
The metabolic disturbances that underlie systemic lupus erythematosus are currently unknown. A metabolomic study was
executed, comparing the sera of 20 SLE patients against that of healthy controls, using LC/MS and GC/MS platforms.
Validation of key differences was performed using an independent cohort of 38 SLE patients and orthogonal assays. SLE
sera showed evidence of profoundly dampened glycolysis, Krebs cycle, fatty acid b oxidation and amino acid metabolism,
alluding to reduced energy biogenesis from all sources. Whereas long-chain fatty acids, including the n3 and n6 essential
fatty acids, were significantly reduced, medium chain fatty acids and serum free fatty acids were elevated. The SLE
metabolome exhibited profound lipid peroxidation, reflective of oxidative damage. Deficiencies were noted in the cellular
anti-oxidant, glutathione, and all methyl group donors, including cysteine, methionine, and choline, as well as
phosphocholines. The best discriminators of SLE included elevated lipid peroxidation products, MDA, gamma-glutamyl
peptides, GGT, leukotriene B4 and 5-HETE. Importantly, similar elevations were not observed in another chronic
inflammatory autoimmune disease, rheumatoid arthritis. To sum, comprehensive profiling of the SLE metabolome reveals
evidence of heightened oxidative stress, inflammation, reduced energy generation, altered lipid profiles and a pro-
thrombotic state. Resetting the SLE metabolome, either by targeting selected molecules or by supplementing the diet with
essential fatty acids, vitamins and methyl group donors offers novel opportunities for disease modulation in this disabling
systemic autoimmune ailment.
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Introduction
SLE is a systemic autoimmune disease resulting in chronic
activation of self-reactive lymphocytes and pro-inflammatory
myeloid cells, and inflammation targeting multiple end organs
including the kidneys, brain, joints and skin. The molecular basis
for the various manifestations of this autoimmune disease and the
impact of the systemic autoimmune process on basic metabolic
processes in the body are currently obscure. In addition, the
currently available yardsticks to diagnose and prognosticate the
disease are far from optimal.
In search for novel insights on the disease, as well as potential
disease markers, serum samples from SLE patients were subjected
to a comprehensive metabolic scan using LC/MS and GC/MS
based platforms, and a library of .2000 metabolite standards.
Statistically significant differences were noted in .100 metabo-
lites, falling into several metabolic pathways. The primary
metabolic scan and subsequent validation assays using an
independent cohort of subjects reveal metabolic imbalances in
multiple processes, including glycolysis, the Krebs cycle, fatty acid
(FA) b-oxidation, lipid biosynthesis, eicosanoid biosynthesis, and
methyl group metabolism. The lupus metabolome was also
marked by elevated oxidative stress, insufficient substrates for
energy biosynthesis, imbalanced lipid profiles, and elevated
inflammatory markers. In addition to providing novel insights on
the metabolic fabric underlying SLE, these studies also point to
potential disease markers, therapeutic targets, and imbalances that
may be amenable to dietary correction.
Results
For the primary metabolomic scan, serum from 20 SLE patients
(whose particulars are summarized in Table 1) was compared to
serum metabolities of 9 healthy controls, using a combined LC/
MS and GC/MS based approach, and a library of .2000
metabolite standards. In comparing the metabolites in SLE sera
and healthy controls, .100 metabolites were significantly different
in SLE, as tabulated in Supplementary Table S1. Reference to the
Kyoto Encyclopedia of Genes and Genomes (KEGG, release 41.1,
http://www.genome.jp/kegg) helped identify the metabolic path-
ways that the dysregulated metabolites belonged to. A substantial
fraction of the observed differences pertained to energy metabo-
lism. Energy from carbohydrates can be derived through
glycolysis. This potential energy source was evidently reduced in
SLE, extrapolating from the significant reduction in key
intermediates in this pathway including glycerol-3 phosphate,
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derived via the Krebs cycle; however, this was also significantly
dampened in SLE patients, as marked by the reduced serum levels
of malate, citrate and a-ketoglutarate in SLE sera (Fig. 1D–1F).
Energy derivation from lipids was also evidently reduced in SLE,
based on the significantly reduced levels of intermediates of b-
oxidation, 1,2 propanediol and 3-hydroxybutyrate (BHBA)
(Fig. 1G–1H, and Supplementary Table S1). In the absence of
energy derivation from carbohydrates and lipids, amino acids
could emerge as potential energy sources. However, all ketogenic
and glucogenic amino acids (with the exception of arginine) were
also significantly dampened in SLE (Fig. 1I; Supplementary
Table S1).
Another cluster of molecules that were significantly reduced in
SLE included all long chain FA and acyl-carnitines, which are
required for ferrying FA into the mitochondria for b-oxidation and
energy release, as captioned in the heatmap in Fig. 2A.
Interestingly, all essential FA (which are FA that cannot be
synthesized by the body, but are of dietary origin) were also
significantly reduced in SLE. These included the polyunsaturated
fatty acids (PUFA), both n3-PUFA (a-linolenic acid, eicosapen-
taenoate or EPA, docosahexaenoate or DHA) as well as n6-PUFA
(linoleic acid, c-linolenic acid, dihomo c-linolenate or DGLA, and
dihomolinoleate) (Fig. 2A; Supplementary Table S1). In contrast
to the reduction in long-chain FA, SLE sera exhibited elevated
levels of medium chain FA (Fig. 2A). An independent assay using
an orthogonal platform confirmed the significantly elevated levels
of free FA (FFA), in an independent cohort of SLE patients
(Fig. 2B). Collectively, these studies indicate that free FA of
medium chain length are elevated in SLE, while long chain FA
and essential PUFA were reduced.
SLE sera exhibited a profound degree of lipid peroxidation, as
marked by the elevated levels of the products, 9-HODE and 13-
HODE, with these elevations being even more pronounced in
patients with active disease (Fig. 2C). These observations were
validated using an independent platform and independent serum
samples (Fig. 2D). These findings point to an increased level of
oxidative stress in SLE. Concordant with these findings, the levels
of the leading intracellular anti-oxidant, glutathione (GSH) was
significantly reduced in SLE (Fig. 2E).
Methyl group donors, which are necessary for the regeneration
of glutathione, were all significantly reduced in SLE, including
methionine, cysteine, and choline (Fig. 2F–H). The reduced
choline levels were, as one would predict, accompanied by
Figure 1. Key metabolic imbalances in SLE affecting carbohydrate, lipid or amino acid metabolism. The sera of 20 SLE patients and 9
healthy controls were comprehensively scanned for differences in small molecules using LC/MS and GC/MS platforms, referred to as the
‘‘metabolomic scan’’. Shown are the mean metabolite levels of 3 glycolytic intermediates (A–C), three Kreb’s cycle intermediates (D–F), and two
products of fatty acid b-oxidation (G–H). Open bars=healthy controls; closed bars=SLE patients. (*,P,0.05; **,P,0.01; ***,P,0.001). Plotted in (I) is a
heatmap of serum amino acid levels in healthy subjects (first 9 columns) versus SLE patients (rightmost 20 columns), as determined by the
metabolomic scan described above. Red=elevated; green=reduced, relative to the mean levels of the metabolite within the 29 study subjects. The
actual mean levels of the metabolites are listed in Supplementary Table S1.
doi:10.1371/journal.pone.0037210.g001
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Figure S1). Besides methyl group donors, the regeneration of
glutathione requires various co-factors, including vitamin B6; this
vitamin was significantly reduced in SLE sera, with the degree of
reduction correlating with disease activity (Fig. 2I) This was
validated using an independent cohort of SLE sera (Fig. 2J).
Vitamin B5 and alpha-tocopherol were also reduced in SLE sera
(Supplementary Table S1).
In contrast to the reduced levels of most metabolites, a couple of
metabolites were significantly elevated in SLE sera, as summarized
in the heatmap in Fig. 3A. Besides the increase in lipid
peroxidation products (9-HODE and 13-HODE), several gam-
ma-glutamyl peptides, and two eicosanoid metabolites in the n6-
PUFA pathway, Leukotriene B4 (LTB4) and 5-HETE were also
significantly elevated in SLE. Elevations were also noted in the
serum levels of fibrin-degradation peptides and bradykinin in SLE
(Supplementary Table S1). A Random Forest analysis was
performed to identify the metabolites that had the greatest
discriminatory potential to distinguish SLE from controls. The
best discriminators included serum levels of gamma-glutamyl
peptides, 5-HETE, leukotriene B4, bradykinins, fibrin degradation
products and lipid peroxidation products (Fig. 3B). The increases
in LTB4 and 5-HETE were validated using independent assay
platforms and an independent cohort of SLE patients (Fig. 3C–D).
As noted above, almost all gamma-glutamyl peptides were also
significantly elevated in SLE (Fig. 3A). These peptides not only
indicate a vigorous attempt to generate glutathione, they also
suggest that the responsible enzyme, gamma-glutamyl transami-
nase, GGT, may be more active or elevated in SLE. This
prediction was confirmed using an independent assay and an
independent cohort of SLE patients (Fig. 3E).
To gauge the disease specificity of these metabolic markers, they
were next examined in another pro-inflammatory, chronic,
systemic autoimmune disease, rheumatoid arthritis (RA). The
alterations in serum leukotriene B4, MDA, GGT, and glutathione
noted in sera from RA patients were not as profound as those
observed in SLE sera (Fig. 4A–D). Importantly, receiver operator
curves (ROC) underscored the excellent predictive values of serum
leukotriene B4 (AUC=0.99), lipid peroxidation marker MDA
(AUC=0.92), GGT1 (AUC=0.97), and glutathione (AUC=0.84)
in distinguishing SLE from healthy controls (Fig. 4E–H; redlined).
Indeed, all 4 markers were also very effective in distinguishing SLE
from RA, as revealed by the respective (black, dotted) ROC curves
in Fig. 4E–H. Interestingly, RA patients exhibited modest
elevations in serum MDA and reduction in glutathione compared
to healthy controls, though not as pronounced as those seen in
SLE (Fig. 4B, 4D).
A couple of metabolite levels in SLE sera showed significant
association with some of the medications the patients were on,
including valine, urate, phenylalanine, leucine, citrulline and
methyl butryl carnitine with prednisone, acetaminophen sulfate
and acetamidophenylglucoronide with lisinopril, and guanosine,
theophylline and tryptophan betaine with mycophenolic acid, as
listed in Supplementary Table S1. Besides these, the other
metabolic changes described in this report showed no association
with the nature of the medications the patients were on. We have
re-evaluated this analysis with the validation data sets, and have
confirmed that the serum levels of MDA, GSH, Leukotriene B4
and GGT1 in SLE patients showed no significant association or
correlation with corticosteroid, plaquenil or MMF therapy, even
when the dosages were factored in.
Discussion
This first comprehensive profiling of the metabolomic landscape
in systemic lupus erythematosus reveals a wide array of
disturbances, as summarized in Figure 5. First and foremost is
the profound degree of shutdown of all energy generating
pathways, including glycolysis (Fig. 5A), Krebs cycle (Fig. 5B), b-
oxidation of lipids (Fig. 5C), and the pool of available amino acids
(Fig. 5D). Assuming these changes are reflective of intracellular
changes within these patients, these findings point to a drastic
reduction of ATP generation, and are consistent with earlier
reports indicating that SLE T-cells are less efficient at ATP
generation [1]. We postulate that this may in part represent the
molecular basis for the chronic fatigue that SLE patients typically
experience, though this needs to be formally proven.
Several imbalances were also noted in the patients’ lipid profiles.
Whereas all long chain FA were reduced (Fig. 2, 5E), medium
chain FA were elevated. Whereas the former are primarily
synthesized de novo, the latter are often of dietary origin, since
they are better absorbed. The reduced long chain FA may be due
in part to the reduced availability of the component building
blocks - acyl coA, as well as available co-factors. In addition, the
raised free fatty acids and medium chain FA levels, coupled with
the reduction in essential FA (both n3-PUFA and n6-PUFA;
Fig. 5F) may point to a diet that is high in saturated:unsaturated
ratios. Other than dietary differences, the significant reduction in
essential FA could also be due to accelerated metabolic
consumption or conversion, either through lipid peroxidation or
heightened leukotriene synthesis (Fig. 5G). Whereas n3-PUFAs are
significantly reduced (and possibly peroxidized), the downstream
Table 1. Demographics and Clinical characteristics of SLE
patients used for the metabolomic profiling.
No. 20
Female, no. 15
Age, median, years (range) 33.8 (18–40)
Race: African American/Hispanic, no. 9/10
BMI, kg/M
2, median (interquartile) 29.9 (22.5–36.7)
SLEDAI, median (range) 5 (0–18)
Protein:creatinine ratio, mg/mg, mean 2.388
Serum Cr, mg/dl, mean 1.22
Positive anti-dsDNA, no. 8
Hypocomplementemia, no. (total no.tested) 9 (19)
Comorbidities
Diabetes Melitus 1
Hypertension 14
Dyslipidemia 4
Deep venous thromboembolism 4
Cardiovascular disease 1
Others 7
Current medications, no.
Prednisone 15
Mycophenolic acid 8
Azathioprine/MTX 3
Cyclophosphamide 2
Angiotensin blocking agents 7
Hydroxychloroquine 9
doi:10.1371/journal.pone.0037210.t001
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PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e37210Figure 2. Lipid profiles and methyl group donors in SLE. Plotted in the heatmap in (A) are the serum levels of long chain fatty acids (FA) and
medium chain FA in 9 healthy controls and 20 SLE subjects, as determined by the metabolomic scan. Presentation details are as in Fig. 1(I). In the
metabolomic scan, additional differences were noted in the serum levels of 9-HODE and 13-HODE (C), methionine (F), cysteine (G), choline (H) and
vitamin B6 (I); presentation details are as in Fig. 1. In (C) and (I), the SLE patients have been segregated into 2 groups - mild SLE (SLEDAI ,6; N=10)
and active SLE (SLEDAI .5; N=10). Also plotted are validation assays for serum levels of free fatty acids (FFA; B), the lipid peroxidation marker, MDA
(D), glutathione (GSH; E), and vitamin B6 (J), ascertained in an independent cohort of 38 SLE patients and 14 healthy controls, using commercially
available assays, independent of the original metabolomic scan. Each dot represents data from an individual subject (*,P,0.05; **,P,0.01;
***,P,0.001).
doi:10.1371/journal.pone.0037210.g002
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leukotriene B4 are significantly elevated in SLE. Dampened n3-
PUFA:n6-PUFA ratios may engender a pro-inflammatory milieu,
as reported by others [2,3]. Collectively, the observed lipid
imbalances, pro-inflammatory milieu and the pro-thrombotic state
in SLE resonate well with the increased cardiovascular complica-
tions documented in SLE [4,5,6].
The profound degree of lipid peroxidation seen in SLE is
likely to be a readout of increased oxidative damage due to the
generation of free radicals in the mitochondria. Indeed,
increased oxidative stress and the reduced availability of anti-
oxidants in SLE have been documented in previous reports
[7,8]. Our present findings confirm the reduced levels of the key
intracellular antioxidant, glutathione (GSH) in SLE (Fig. 2, 5I).
Figure 3. Metabolic markers that best distinguish SLE from healthy controls. Plotted in (A) is a heatmap of a cluster of metabolites that
were elevated in SLE sera; presentation details are listed in Fig. 1(I). The metabolites that were best at discriminating SLE from controls (based on the
results from the original metabolomic scan of 20 SLE patients and 9 healthy controls) were identified and ordered using a Random Forest analysis
algorithm (B). The markers are listed in decreasing order of disease-discriminatory potential. Also plotted are validation assays for serum levels of
leukotriene B4 (C), 5-HETE (D), and serum GGT1 (E) ascertained in an independent cohort of 38 SLE patients and 14 healthy controls, using
commercially available kits, independent of the original metabolomic scan (*,P,0.05; **,P,0.01; ***,P,0.001).
doi:10.1371/journal.pone.0037210.g003
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generation and/or increased consumption. The generation of
GSH and its intermediates requires component amino acids,
methyl group donors, and various cofactors, all of which are
profoundly reduced in SLE (Fig. 1I, 2F–J). The reduction in
methyl group donors (e.g., methionine, choline, cysteine;
Fig. 5H) is also likely to curtail other molecular mechanisms
that are dependent upon methylation, including DNA and
histone methylation, lipid metabolism, and the synthesis of
various mediators. Indeed, global DNA hypomethylation,
accompanied by the activation of various genes has been
documented in human SLE [9,10], and this may in part be
attributed to the drastic reduction in available methyl group
donors in these patients. There are however indications that the
system is vigorously attempting to generate GSH, based on the
striking elevations in various gamma-glutamyl peptides, as well
as dimethyl glycine, both of which are by-product footprints of
these metabolic cascades (Fig. 3A, 5I; Supplementary Table S1).
The reduced levels of choline are, as expected, accompanied
by reduced levels of phosphocholines (Fig. 5H). Since phospho-
cholines constitute integral membrane components, this deficien-
cy could adversely impact membrane structure/dynamics, as well
as cell signaling and function in SLE patients – predictions that
await formal testing. Furthermore, reduced phosphocholine will
impair the export of lipids as VLDL out of the liver. In the face
of elevated FFA, these changes could pave the way towards
hepatic steatosis and fatty liver, and their associated co-
morbidities. Whether SLE patients harbor these hepatic alter-
ations warrants systematic study.
Presently, it is unclear if the serum metabolic changes
observed in this study arise from free metabolites in the sera
or from cell-derived particles (e.g., cellular debris, exosomes,
etc). Irrespective, these disturbances are likely to be reflective of
the intracellular metabolic alterations in these patients, arising
from leukocytes or non-immune cells (e.g., endothelial cells,
hepatocytes, etc). Though the cascades diagramed in Fig. 5
might have arisen from multiple independent triggers, it is
tempting to speculate that subsets of these alterations may be
interconnected to each other, and to immune activation. For
instance, robust and repeated activation of autoreactive
lymphocytes (by autoantigens), various myeloid cells and other
non-immune cells may be the wellspring of redox radicals. This
in turn could result in profound oxidative damage (including
lipid peroxidation) and consumption of GSH. Refocusing all of
the cell’s efforts towards GSH regeneration could have rippling
effects on the cellular stores of amino acids, methyl groups and
various co-factors, the depletion of which may dysregulate
additional interlinked metabolic pathways. Whether genetic
and/or epigenetic factors might also directly regulate any of
the cascades depicted in Fig. 5 is an open question. Whereas
some of the observed changes may be the consequence of
disease, others may well play a role in causing or aggravating
various manifestations of the disease, as implied in Fig. 5 (pink
boxes).
These metabolic alterations have potential diagnostic and
therapeutic implications. Based on the validation assays using
independent serum samples and independent assay platforms, the
serum levels of leukotriene B4, the lipid peroxidation marker
MDA, gamma-glutamyl peptides or GGT, and glutathione
emerge as excellent predictors of SLE, with superior specificity
and sensitivity profiles (Fig. 4), effectively differentiating SLE from
healthy controls as well as another pro-inflammatory, chronic
systemic autoimmune disease, RA. Moreover, the SLE-associated
metabolic changes reported here are distinct from those associated
with other diseases whose metabolomes have been comprehen-
sively profiled, including other autoimmune diseases [11,12] and
Figure 4. Sensitivity and specificity profiles of new metabolic markers in SLE. The levels of the 4 markers indicated were tested in serum
samples from RA patients (open dots; N=20) and SLE patients (closed dots; N=38) (A–D). Each dot represents data from a single individual.
(*,P,0.05; **,P,0.01; ***,P,0.001). The dotted line represents the mean serum levels in healthy controls (N=14). The potential of the different
markers in distinguishing SLE from healthy controls (red bold line), or from RA disease controls (black dotted line) were also analyzed using ROC
curves, as displayed for leukotriene B4 (E), MDA (F), GGT1 (G) and glutathione (H), based on the serum levels observed in the independent cohort of
38 SLE patients, 20 RA patients and 14 healthy controls, in the validation assays plotted in A–D. The ROC curves plot (1-Specificity) % on the x-axis
versus the Sensitivity (%) on the Y-axis, for each marker. AUC=Area under ROC curve.
doi:10.1371/journal.pone.0037210.g004
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were significantly altered in SLE sera, they did not correlate
significantly with SLEDAI, anti-dsDNA titers, renal disease or
disease duration (data not shown). Interestingly, although the
peroxidation marker MDA did not correlate with disease activity
in SLE, other lipid peroxidation markers such as 9/13-HODE did
show higher associations with higher disease activity (Fig. 2C); the
significance of these subtle differences currently remain unknown.
Interestingly, the increased serum levels of leukotriene B4 and
reduced serum levels of glutathione correlated with age, alluding
to the importance of factoring in age differences when examining
these two markers.
Finally, the metabolic landscape in SLE may lend itself to
disease modulation by targeted therapeutics and/or dietary
means. The reduced levels of n3-PUFA (which is totally diet-
derived), could perhaps be corrected by dietary supplementation
particularly since fish oil supplements have been shown to be
effective in murine lupus [14], and in limited clinical trials in SLE
patients [15]. The reduced levels of various co-factors call for
adequate vitamin supplementation (in particular, the B vitamins)
as adjunctive therapy in SLE. Since dietary choline is the major
source of methyl groups, supplementing the diet with choline and
its precursors (notably, lecithin) may also be important. Whether
dietary anti-oxidants can alter the intra-cellular redox balance in
SLE remains to be established. Regardless, resetting the imbal-
Figure 5. An overview of the metabolic imbalances in SLE. The most significant metabolic alterations in SLE have been organized into
different biochemical pathways, including glycolysis (A), Krebs cycle (B), fatty acid oxidation (C), amino acid pools (D), lipid biosynthesis (E), essential
FA (F), eicosanoid biosynthesis (G) and methyl group interchange pathways (H) leading to glutathione generation (I). Metabolites that were elevated
in SLE are in red font, while reduced metabolites are in green font. Mitochondrial events are blue-boxed, while events that take place in the
endoplasmic reticulum are yellow-boxed. Salient metabolic consequences that can potentially contribute to the manifestations of SLE are highlighted
in pink.
doi:10.1371/journal.pone.0037210.g005
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disease modulation in SLE.
Materials and Methods
Patient Samples
For the primary metabolomic scan, all 20 SLE patients were
drawn from the Renal Clinic at UT Southwestern Medical
Center, Dallas, TX, of whom 10 had active renal disease with
SLEDAI .5. Patients were recruited as and when they were seen
for their routine outpatient clinic visits, as long as they met all
recruitment criteria. The patients’ characteristics and the medica-
tions they were on are detailed in Table 1. The mean body mass
index (BMI) of the SLE patients (29.9) was not significantly
different from that of the general population in Dallas (mean
BMI=29; N=6101), from which all healthy controls were drawn
[16]. Healthy control individuals in the Dallas Autoimmune
Disease Registry [17] were recruited from the Dallas area and
screened to be sure that the donor did not have autoimmune
disease personally or in first-degree relatives; 78% of the controls
were African American or Hispanic females. The mean BMI of
the healthy controls used in this study was 26.9, not significantly
different from that of the SLE patients studied (P.0.10), while
their mean age was 36. For all validation assays, an independent
cohort of SLE patients (N=38; average age=38; average
BMI=28.7; average SLEDAI=7) was used, drawn from the
rheumatology clinic at Albert Einstein College of Medicine, New
York. More than 80% of these subjects were either of African-
American or Hispanic origin. Disease activity was gauged using
SLEDAI (SLE disease activity index) [18]. All Rheumatoid
Arthritis (RA) patients were also drawn from the Albert Einstein
College of Medicine, New York, and were age, gender and
ethnicity matched to the SLE patients.
All human research was approved by the UT Southwestern
institutional review board (IRB). All research was conducted with
informed written consent, and all clinical investigation were
conducted according to the principles expressed in the Declaration
of Helsinki.
Metabolomic Profiling - Sample Preparation
The metabolomic profiling procedures have been detailed
previously [19]. Human sera were obtained from healthy controls
(N=9) and SLE patients (N=20). Serum samples were collected
using BD vacutainer serum tubes (Ref 367820), spun at 1500 RCF
for 10 minutes at room temperature. The retrieved serum was
then aliquoted and stored in 280. For the metabolomic analysis,
frozen serum aliquots were thawed, and processed using an
automated MicroLab STARH system (Hamilton Company), using
a series of organic and aqueous extractions to remove the protein
fraction in sera while allowing maximum recovery of small
molecules. Recovery standards were added prior to the first step in
the extraction process for QC purposes. The resulting extract was
divided into two fractions; one for analysis by LC and one for
analysis by GC. Samples were placed briefly on a TurboVapH
(Zymark) to remove the organic solvent, and then frozen and dried
under vacuum. Samples were then prepared for the appropriate
instrument, either LC/MS or GC/MS.
Liquid Chromatography/Mass Spectrometry (LC/MS, LC/
MS
2)
The LC/MS portion of the platform was based on a Waters
ACQUITY UPLC and a Thermo-Finnigan LTQ-FT mass
spectrometer, which had a linear ion-trap (LIT) front end and a
Fourier transform ion cyclotron resonance (FT-ICR) mass
spectrometer backend. The sample extract was split into two
aliquots, dried, then reconstituted in acidic or basic LC-
compatible solvents, each of which contained 11 or more
injection standards at fixed concentrations. One aliquot was
analyzed using acidic positive ion optimized conditions and the
other using basic negative ion optimized conditions in two
independent injections using separate dedicated columns.
Extracts reconstituted in acidic solvents were gradient eluted
using water and methanol both containing 0.1% formic acid,
while the basic extracts, which also used water/methanol,
contained 6.5 mM ammonium bicarbonate. The MS analysis
alternated between MS and data-dependent MS
2 scans using
dynamic exclusion. For ions with counts greater than 2 million,
an accurate mass measurement could be performed. Accurate
mass measurements could be made on the parent ion as well as
fragments. The typical mass error was less than 5 ppm.
Fragmentation spectra (MS/MS) were typically generated in
data dependent manner, while targeted MS/MS was employed
in the case of lower level signals.
Gas Chromatography/Mass Spectrometry (GC/MS)
The samples destined for GC/MS analysis were re-dried under
vacuum desiccation for a minimum of 24 hours prior to being
derivatized under dried nitrogen using bistrimethyl-silyl-triflour-
oacetamide (BSTFA). A 5% phenyl-based GC column was used,
with the temperature being ramped from 40u to 300uC over a 16
minute period. Samples were analyzed on a Thermo-Finnigan
Trace DSQ fast-scanning single-quadrupole mass spectrometer
using electron impact ionization. The instrument was tuned and
calibrated for mass resolution and mass accuracy on a daily basis.
Compound Identification
Identification of known chemical entities was based on
comparison to a metabolomic library with .2000 entries of
purified standards. The combination of chromatographic proper-
ties and mass spectra gave an indication of a match to the specific
compound or an isobaric entity in the library. Additional entities
could be identified by virtue of their recurrent chromatographic
and mass spectral nature. These compounds have the potential of
being identified by future acquisition of matching purified
standards or by classical structural analysis.
Validation Assays
All validation studies were performed using orthogonal methods
other than GC/MS or LC/MS. Glutathione (GSH) was measured
using a Glutathione Assay kit purchased from Cayman Chemical,
Ann Arbor, MI. Serum MDA was determined using a TBARS
Assay kit purchased from Cayman Chemical, Ann Arbor, MI.
Free Fatty Acids (FFA) were measured using a Free Fatty Acid
Quantification kit purchased from Abcam, Cambridge, MA.
Serum GGT1 was measured using a Human Gamma Glutamyl-
transferase 1 (GGT1) ELISA kit purchased from USCN Life
Sciences InC., Wuhan, China. Serum vitamin B6 was assayed by
AntiCancer, Inc., San Diego, CA. All assays were performed
following the manufacturer’s instructions.
Statistical Calculation
For pair-wise comparisons, Welch’s t-tests and/or Wilcoxon’s
rank sum tests were used. For classification of the best
discriminators, Random Forest analysis was used. Random
Forests give an estimate of how well we can classify individuals
in a new data set into different study groups (e.g., SLE versus
healthy controls) [20] in contrast to a t-test, which tests whether
Metabolomics of Lupus
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Random Forests create a set of classification trees based on
continual sampling of the experimental units and compounds.
Then each observation is classified based on the majority votes
from all the classification trees [5]. Statistical analyses were
performed using ‘‘R’’ from the Free Software Foundation, Inc.
(http://cran.r-project.org/) or Array Studio (Omicsoft, Inc.).
Supporting Information
Figure S1 Serum phosphocholine levels in SLE. Plotted
are the serum levels of phosphocholines in 9 healthy controls and
20 SLE subjects, as determined by the metabolomic scan.
Presentation details are as in Fig. 1. The SLE patients have been
segregated into 2 groups - mild SLE (SLEDAI ,6; N=10) and
active SLE (SLEDAI .5; N=10). These results are detailed in
Supplementary Table S1.
(TIF)
Table S1 Mean metabolite levels in SLE and healthy
control sera.
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